Shaanxi Kemai Pharmaceutical Development

Shaanxi Kemai Pharmaceutical Development is a biopharmaceutical company headquartered in Xi'an, China, dedicated to the discovery and development of novel therapeutics for metabolic disorders and oncology. The company's primary focus is on addressing hyperuricemia and gout through the development of potent URAT1 inhibitors, such as its lead candidate KM-818, which is currently in Phase 2 clinical trials. In addition to its small molecule pipeline, Kemai develops modernized traditional Chinese medicine (TCM) products like the Jingtai Capsule for gout management. The company maintains a strategic partnership with Xi'an Taikemai Pharmaceutical Technology to utilize comprehensive CRO services for its internal R&D programs.